Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,752 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: yamada y. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: yamada y. Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8. Cancer Chemother Pharmacol. 2018. PMID: 29737372
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
Imai H, Yamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: yamada y. Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14. Chemotherapy. 2018. PMID: 30107372
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H, Yamada Y, Minemura H, Sugiyama T, Kotake M, Kaira K, Kanazawa K, Nakamura Y, Kasai T, Shibata Y, Kaburagi T, Minato K; Gunma-Ibaragi-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: yamada y. Thorac Cancer. 2018 Dec;9(12):1699-1706. doi: 10.1111/1759-7714.12884. Epub 2018 Oct 3. Thorac Cancer. 2018. PMID: 30281216 Free PMC article.
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Kaburagi T, Kiyoshima M, Yamada Y, Tamura T, Saito K, Inagaki M, Hizawa N, Sato Y, Shiozawa T, Sekine I, Ishikawa H, Kurihima K, Sakai M, Kamiyama K, Kimura M, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Miyazaki K, Yamashita T, Hayashi S, Funayama Y, Nomura A. Okauchi S, et al. Among authors: yamada h, yamada y. Anticancer Res. 2020 Feb;40(2):957-964. doi: 10.21873/anticanres.14029. Anticancer Res. 2020. PMID: 32014940
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Kasai T, Mori K, Kishi K, Kaburagi T, Hosomi Y, Imai H, Yamada Y, Yomota M, Moriguchi S, Seike M, Minato K, Gemma A; Tokyo Cooperative Oncology Group. Kasai T, et al. Among authors: yamada y. Int J Clin Oncol. 2020 May;25(5):867-875. doi: 10.1007/s10147-020-01629-6. Epub 2020 Feb 14. Int J Clin Oncol. 2020. PMID: 32060768 Clinical Trial.
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
Miyazaki K, Sato S, Kodama T, Numata T, Endo T, Yamamoto Y, Shimizu K, Yamada H, Hayashihara K, Okauchi S, Satoh H, Yamada Y, Tamura T, Saito K, Kikuchi N, Kurishima K, Ishikawa H, Watanabe H, Shiozawa T, Hizawa N, Funayama Y, Hayashi S, Nakamura H, Yamashita T. Miyazaki K, et al. Among authors: yamada h, yamada y. In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998. In Vivo. 2020. PMID: 32606173 Free PMC article.
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Imai H, Minemura H, Kishikawa T, Yamada Y, Suzuki K, Umeda Y, Wasamoto S, Kasahara N, Ishihara S, Yamaguchi O, Naruse I, Uchino J, Mori K, Kanazawa K, Shibata Y, Kasai T, Kaburagi T, Kaira K, Minato K. Imai H, et al. Among authors: yamada y. Thorac Cancer. 2020 Oct;11(10):2867-2876. doi: 10.1111/1759-7714.13622. Epub 2020 Aug 26. Thorac Cancer. 2020. PMID: 32844570 Free PMC article.
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, Yamada H, Endo T, Nakamura R, Inage Y, Satoh H, Iguchi K, Saito K, Inagaki M, Kikuchi N, Kurishima K, Ishikawa H, Sakai M, Kamiyama K, Shiozawa T, Hizawa N, Sekine I, Sato Y, Funayama Y, Miyazaki K, Kodama T, Hayashi S, Nomura A, Nakamura H, Furukawa K, Yamashita T, Okubo H, Suzuki H, Kiyoshima M, Kaburagi T. Yamada Y, et al. Among authors: yamada h. Anticancer Res. 2020 Oct;40(10):5757-5764. doi: 10.21873/anticanres.14592. Anticancer Res. 2020. PMID: 32988903 Clinical Trial.
9,752 results